The economics of abiraterone acetate for castration-resistant prostate cancer

被引：12
|
作者：
Dellis, Athanasios [1 ,2 ]
Papatsoris, Athanasios G. [1 ,3 ,4 ,5 ]
机构：
[1] Sismanoglio Gen Hosp, Univ Dept Urol, Athens, Greece
[2] Arete Hosp, Univ Dept Gen Surg, Athens, Greece
[3] Hellen Grp Genitourinary Canc, Athens, Greece
[4] Barts & London NHS Trust, Dept Urol, London, England
[5] Inst Mol Med & Biomed Res, Athens, Greece
来源：
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2014年 / 14卷 / 02期
关键词：
metastatic; economics; cost/benefit; prostate cancer; abiraterone acetate; castration resistant; CLINICAL ACTIVITY; SOLID TUMORS; THERAPY; PHARMACOECONOMICS; ENZALUTAMIDE; PREVENTION; DOCETAXEL; DENOSUMAB; CYP17; COST;
D O I：
10.1586/14737167.2014.891444
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Abiraterone acetate is an oral medication that has recently been granted approval for the treatment of metastatic castration resistant prostate cancer (mCRPC) prior and/or after chemotherapy with docetaxel. In this article we assess the economics of abiraterone acetate in mCRPC. Relevant studies demonstrated that abiraterone acetate had a minimal budget impact on health plans. A relevant advantage was the cost savings due to the lack of chemotherapy-related side effects as well as the ease of administration. The results of cost/benefit comparative studies with other novel agents (i.e. cabazitaxel, enzalutamide, sipuleucel-T) are warranted as well as the close collaboration between urologists and medical oncologists.
引用
收藏
页码：175 / 179
页数：5
相关论文
共 50 条
  • [1] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    [J]. ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [2] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    [J]. DRUGS, 2011, 71 (15) : 2067 - 2077
  • [3] The development of abiraterone acetate for castration-resistant prostate cancer
    Grist, Emily
    Attard, Gerhardt
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (06) : 289 - 294
  • [4] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [5] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    [J]. Drugs, 2012, 72 (2) : 192 - 192
  • [6] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [7] Abiraterone and castration-resistant prostate cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2013, 14 (02): : E48 - E48
  • [8] Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer
    Mckay, R. R.
    Werner, L.
    Fiorillo, M.
    Nakabayashi, M.
    Kantoff, P. W.
    Taplin, M-E
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (04) : 398 - 405
  • [9] Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer
    Beardo-Villar, P.
    Ledo-Cepero, M. J.
    Gavira-Moreno, R.
    Soto-Delgado, M.
    Soto-Vittalba, J.
    Alvarez-Ossorio, J. L.
    Juarez-Soto, A.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (05): : 339 - 345
  • [10] Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer
    R R McKay
    L Werner
    M Fiorillo
    M Nakabayashi
    P W Kantoff
    M-E Taplin
    [J]. Prostate Cancer and Prostatic Diseases, 2016, 19 : 398 - 405
12345